Dariusz Woszczyk

Dariusz Woszczyk

Auto-generated profile, based on publicly available information

Dariusz Woszczyk

Institute of Medical Sciences, University of Opole, Opole, Poland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
ADAlemnew F Dagnew
Alemnew F Dagnew
OIOsman Ilhan
Osman Ilhan
WLWon-Sik Lee
Won-Sik Lee
DWDariusz Woszczyk
Dariusz Woszczyk
JKJae-Yong Kwak
Jae-Yong Kwak
Francesco ZajaFrancesco Zaja
Francesco Zaja

23 November 2022 in Future Oncology
Verified
Journal Article
Open access
SVSrdan Verstovsek
Srdan Verstovsek
Haifa Kathrin Al-AliHaifa Kathrin Al-Ali
Haifa Kathrin Al-Ali
JMJohn Mascarenhas
John Mascarenhas
Andrew PerkinsAndrew Perkins
Andrew Perkins
AVAlessandro Maria Vannucchi
Alessandro Maria Vannucchi
JKJean-Jacques Kiladjian
Jean-Jacques Kiladjian
Patients with myelofibrosis (MF) who discontinue ruxolitinib due to progression/resistance have poor prognoses. JAK inhibitors control symptoms and reduce spleen volumes with limited impact on unde... Plain language summary Myelofibrosis (MF) is a rare blood cancer that disrupts normal blood cell production and causes fibrosis (tissue thickening/scarring) in bone marrow, reduced red blood cells ... Tweetable abstract Navtemadlin (KRT-232), a potent, selective and orally available MDM2 inhibitor is being explored in the global phase III BOREAS trial in #myelofibrosis patients who are relapsed ... Graphical abstract Clinical Trial Registration: NCT03662126 (ClinicalTrials.gov).

27 April 2018 in Leukemia
Verified
Journal Article
Open access
PDF file
SSStephan Stilgenbauer
Stephan Stilgenbauer
VLVeronique Leblond
Veronique Leblond
RFRobin Foà
Robin Foà
SBSebastian Böttcher
Sebastian Böttcher
OIOsman Ilhan
Osman Ilhan
FBFrancesc Bosch
Francesc Bosch
GREEN (NCT01905943) is a non-randomized, open-label phase IIIb study investigating obinutuzumab alone or plus chemotherapy in chronic lymphocytic leukemia (CLL). We report a preplanned subgroup analysis of 158 previously untreated CLL patients receiving obinutuzumab–bendamustine (G-B). Patients received six 28-day cycles (C) of G-B: obinutuzumab day (D)1/D2 of C1 (25 mg D1/975 mg D2), 1000 mg D8 and D15 of C1, and D1 of C2–6; and bendamustine 70/90 mg/m2 D1 and D2 of C1–6. The primary endpoint was safety/tolerability. Grade ≥3 adverse events (AEs) occurred in 82.3% of patients, including neutropenia (49.4%), thrombocytopenia (12.0%) and febrile neutropenia (10.8%). Serious AEs included neutropenia (12.7%), febrile neutropenia (9.5%) and pneumonia (7.6%). Rates of grade ≥3 infections and infusion-related reactions were 20.3% and 17.1%, respectively. Due to tumor lysis syndrome (TLS; 8.2%), including two associated fatalities (one in another study cohort), additional risk-minimization measures were implemented. Overall response rate was 81.0%. After 32.8 months’ median observation time, 2-year progression-free survival was 81.8%. Minimal residual disease was undetectable in 59.5% (94/158) and 27.8% (44/158) of patients for blood and bone marrow, respectively. Frontline G-B appears to have manageable toxicity with clinical activity in CLL. Careful TLS risk assessment, pretreatment and monitoring is required.

1 September 2021 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
AOAdam Olszewski
Adam Olszewski
AAAbraham Avigdor
Abraham Avigdor
SBSunil Babu
Sunil Babu
ILItai Levi
Itai Levi
HEHerbert Eradat
Herbert Eradat
NHNetanel Horowitz
Netanel Horowitz

10 July 2026 in Rheumatology
Verified
Journal Article
Open access
PDF file
KMKrzysztof Michalak
Krzysztof Michalak
GCGabriela Chlebowska
Gabriela Chlebowska
OSOliwia SęDziak
Oliwia SęDziak
DWDariusz Woszczyk
Dariusz Woszczyk
Introduction: Systemic sclerosis (SSc) remains a challenge due to high mortality and resistance to treatment. Chimeric antigen receptor T-cell (CAR-T) technology (anti-CD19) may offer an opportunity for an immune system reset and long-term disease remission, eliminating the need for lifelong medication. Material and Methods: This narrative review is based on a literature search in the PubMed and Scopus databases from 2023 to 2026. The main search phrases were: “CAR-T in systemic sclerosis”, “CAR-T scleroderma”, and “CAR-T SSc.” Results: CD19-targeted CAR-T therapy led to significant clinical improvement across analyzed cases. The median modified Rodnan skin score decreased by 8–13 points within 3–6 months. Disease activity, measured by the European Scleroderma Trials and Research Group Activity Index (EUSTAR-AI), showed a mean improvement ranging from 2.1 to 4.2 points. Pulmonary function remained stable or improved, with forced vital capacity increasing by up to 7% in responders. The safety profile was manageable, primarily consisting of grade 1 cytokine release syndrome in approximately 75–80% of patients. Conclusions: CD19-targeted CAR-T therapy is a promising investigational option for patients with refractory SSc. Limitations include small study groups and a lack of randomized controlled trials, warranting further validation in ongoing clinical studies.

5 October 2026 in Blood
Verified
Journal Article
Closed access
AOAdam J. Olszewski
Adam J. Olszewski
HEHerbert A. Eradat
Herbert A. Eradat
AAAbraham Avigdor
Abraham Avigdor
NHNetanel Horowitz
Netanel Horowitz
MMMatthew S. McKinney
Matthew S. McKinney
WJWojciech Jurczak
Wojciech Jurczak
Older or medically unfit patients with diffuse large B-cell lymphoma (DLBCL) frequently cannot tolerate standard anthracycline-based immunochemotherapy, creating a persistent unmet clinical need. We conducted a multicenter, international, open-label phase I/II trial evaluating an immunotherapy-based first-line approach using subcutaneous mosunetuzumab in combination with polatuzumab vedotin in previously untreated patients classified as unfit or frail by simplified geriatric assessment (sGA). Participants received six cycles of polatuzumab vedotin with step-up-dosing of subcutaneous mosunetuzumab, followed by mosunetuzumab monotherapy for a planned total of eight cycles. The primary endpoint was objective response rate (ORR) at end of treatment, assessed by independent review using PET-CT Lugano 2014 criteria. Among participants treated at full dose (n=101), the median age was 81 years with 58% classified as unfit and 41% as frail by sGA. The ORR at the end of treatment was 61.4% (95% CI, 51.1-70.9), with a complete response (CR) rate of 56.4%. The best observed ORR and CR rates on therapy were 80.2% and 66.3%, respectively. With a median follow-up of 36.5 months, median investigator-assessed duration of response and overall survival were not reached; estimated 2-year progression-free and overall survival were 52.2% and 62.4%, respectively. Cytokine release syndrome occurred in 30.6% of participants and was predominantly grade 1. Infection-related mortality was observed, largely during the COVID-19 pandemic and among participants classified as frail. This geriatric assessment-guided treatment demonstrated durable efficacy and may represent a potential first-line treatment option for carefully selected unfit or frail patients with newly diagnosed DLBCL. Trial registration: #NCT03677154.